Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -101.6%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $15M | $14M | $18M | $140M | $36M | $210M | $7M | $3M | $517118 | $3M | $3M |
| Enterprise Value | $-2559442 | $-3528962 | $364362 | $135M | $29M | $206M | $8M | $3M | $1M | $3M | $3M |
| P/E Ratio → | -0.16 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.15 | 0.72 | 1.17 | 9.13 | 9.74 | 41.63 | — | 1.56 | 4.65 | 2.24 | 1.64 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -101.6% | -101.6% | -208.3% | -528.7% | -598.2% | -2579.0% | — | -218.0% | -380.4% | -86.6% | -46.4% |
| ROA | -75.0% | -75.0% | -106.5% | -182.0% | -199.4% | -3203.9% | -716.0% | -102.9% | -106.3% | -52.4% | -28.9% |
| ROIC | — | — | -597.9% | -890.5% | — | — | — | -139.6% | -171.2% | -78.0% | -43.8% |
| ROCE | -102.8% | -102.8% | -176.5% | -246.6% | -259.6% | -2733.6% | — | -162.8% | -177.7% | -85.2% | -46.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.39 | 0.94 | 3.34 | — | — | — | 7.43 | 0.03 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.90 | -1.14 | -0.33 | -1.74 | -0.89 | — | -0.16 | 7.02 | 0.03 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -54.30 | -54.30 | -11.12 | -10.69 | -12.60 | -246.77 | -0.56 | -9146.52 | -57.91 | — | — |
Net cash position: cash ($18M) exceeds total debt ($349894)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.10 | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 | 1.52 | 0.04 | 0.01 | 0.16 |
| Quick Ratio | 9.10 | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 | 1.52 | 0.04 | 0.01 | 0.16 |
| Cash Ratio | 7.71 | 7.71 | 2.55 | 2.34 | 4.47 | 4.53 | 0.00 | 0.77 | 0.04 | 0.01 | 0.15 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 1.5% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 33.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 34.5% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $451853 | $324834 | $246625 | $124031 | $49295 | $25396 | $7661 | $7151 | $6976 |
Clinical trial data integrity
According to recent market data, BioVie trades at a price-to-book ratio of 0.15, which, when compared to peers like Athira Pharma at 0.37, suggests that investors are heavily discounting the company's intellectual property due to the recent exclusion of critical clinical trial data from its NE3107 program.
The current valuation appears to reflect a market expectation of significant future dilution or potential asset impairment rather than intrinsic value. Investors should monitor whether this deep discount to book value represents a genuine contrarian opportunity or a rational pricing of the company's inability to reach a commercial inflection point without further capital raises.
Based on reported figures, BioVie's ROIC has remained consistently negative, reaching -4.4% in 2026Q3, which highlights the company's inability to generate productive returns on invested capital while it continues to burn through its remaining cash reserves to fund high-cost, pre-revenue clinical development activities.
The persistent decay in return metrics suggests that the capital allocated to the NE3107 and BIV201 programs has yet to yield any tangible economic value. This trend warrants further investigation into whether management's capital allocation strategy can pivot toward more efficient research pathways or if the current structure is inherently incapable of generating positive returns.
As reported in financial statements, BioVie's current ratio has fluctuated significantly, dropping from 15.83 in 2026Q1 to 9.97 in 2026Q3, indicating that while the company maintains a nominal liquidity cushion, its actual ability to fund long-term clinical operations is rapidly diminishing under current burn rates.
The high current ratio is somewhat deceptive, as it does not account for the substantial accrued liabilities associated with ongoing clinical trials that may not yet be reflected in the balance sheet. Investors should monitor the cash runway closely, as the current liquidity position may be insufficient to survive a prolonged period of regulatory scrutiny or trial redesign.
The price-to-book ratio is the most commonly misapplied metric for BioVie, as it obscures the fact that the company's book value is primarily composed of capitalized R&D costs rather than tangible assets that could be liquidated to satisfy obligations in a distress scenario.
Using P/B to gauge value in this context is misleading because it ignores the binary nature of clinical-stage biotech assets, which are essentially worthless if the underlying drug candidate fails to meet regulatory standards. A more appropriate focus would be the cash-to-burn ratio, which provides a clearer picture of the company's survival horizon than traditional valuation multiples.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIVI stock.
BioVie Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
BioVie Inc.'s return on equity (ROE) is -101.6%. The historical average is -172.3%.
Based on historical data, BioVie Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.